Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 14/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.33 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9865629 | 1.00 | IRAK4 (0.37) | IRAK4GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL15727499 | 0.91 | IRAK4 (0.39) | IRAK4GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL21180014 | 0.91 | IRAK4 (0.39) | IRAK4GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL4378121 | 0.90 | IRAK4 (0.35) | IRAK4ALOX5 | |
| SCHEMBL11920249 | 0.79 | IRAK4 (0.39) | IRAK4GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL9851967 | 0.76 | IRAK4 (0.38) | IRAK4IRAK1 | |
| SCHEMBL12409742 | 0.76 | — | — | |
| SCHEMBL12459955 | 0.76 | — | — | |
| SCHEMBL9865753 | 0.76 | — | — | |
| Hydrochloric Acid SCHEMBL27036387 | 0.74 | IRAK4 (0.39) | IRAK4PDK2IRAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3021879-A2 | METHODS, SYSTEMS, AND COMPOSITIONS FOR PROMOTING BONE GROWTH | Cayman Chemical Company, Incorporated (US) | 2016-05-25 | — | — | EP | disclosed |
| WO-2015009991-A2 | METHODS, SYSTEMS, AND COMPOSITIONS FOR PROMOTING BONE GROWTH | CAYMAN CHEMICAL COMPANY, INC. (US) | 2015-01-22 | — | — | WO | disclosed |
| EP-1408961-B1 | 2 PYRROLIDONE DERIVATIVES AS PROSTANOID AGONISTS | HOFFMANN LA ROCHE (CH) | 2007-07-11 | — | — | EP | disclosed |
| US-6849657-B2 | 2-pyrrolidone derivatives as prostanoid agonists | SYNTEX (U.S.A.) LLC (US) | 2005-02-01 | — | — | US | disclosed |
| EP-1408961-A1 | 2 PYRROLIDONE DERIVATIVES AS PROSTANOID AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-04-21 | — | — | EP | disclosed |
| US-20030064964-A1 | 2-pyrrolidone derivatives as prostanoid agonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-04-03 | — | — | US | disclosed |
| WO-2003007941-A1 | 2 PYRROLIDONE DERIVATIVES AS PROSTANOID AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064964-A1 | 2-pyrrolidone derivatives as prostanoid agonists | PTGER1, PTGER4, PTGIR | IRAK4 748/4885GABRA1 231/4885GABRG2 561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.